TAMSULOSIN TREATMENT OF 19,365 PATIENTS WITH LOWER URINARY TRACT SYMPTOMS
- 1 September 1998
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 160, 784-791
- https://doi.org/10.1097/00005392-199809010-00043
Abstract
We compare the tolerability and blood pressure effects of 0.4 mg. tamsulosin once daily in patients with lower urinary symptoms suggestive of benign prostatic obstruction with or without concomitant disease and/or antihypertensive medication. Data from 2 open label, observational studies (study 1, 9,507 patients treated for 4 weeks and study 2, 9,858 patients treated for 12 weeks) were analyzed for global tolerability and effects on blood pressure stratifying for co-morbidity (none, diabetes, hypertension, other cardiovascular disease) and co-medication (diuretics, beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors). Overall 90 and 95% of patients in studies 1 and 2, respectively, reported good or very good tolerability. While global tolerability was slightly reduced in patients with concomitant disease or some forms of medication (p < 0.05), it was rated as good or very good by more than 90 and 95% of patients even in those groups. In control patients, that is those with neither co-morbidity nor co-medication, the tamsulosin induced blood pressure reductions were similar to those previously reported for placebo treatment but were statistically significant (p < 0.05). Mean additional blood pressure reductions in patients with concomitant disease or medication were not more than 2 mm. Hg. Tamsulosin is well tolerated and has marginal effects on blood pressure in the majority of patients. It largely maintains its good global tolerability and minimal blood pressure effects in patients with cardiovascular co-morbidity or diabetes, or those on co-medication with antihypertensive agents.Keywords
This publication has 17 references indexed in Scilit:
- Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic HyperplasiaUrology, 1998
- Radioreceptor assay analysis of tamsulosin and terazosin pharmacokineticsBritish Journal of Clinical Pharmacology, 1998
- Clinical comparison of selective and non‐selective &agr;1A‐adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing dosesBJU International, 1997
- Prostatic α1-adrenoceptors and uroselectivityThe Prostate, 1997
- Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year resultsUrology, 1996
- Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α1‐adrenoceptor subtypes and in human prostateJournal of Autonomic Pharmacology, 1996
- Doxazosin in benign prostatic hyperplasia: Effects on blood pressure and urinary flow in normotensive and hypertensive menUrology, 1995
- Practice Trends in the Diagnosis and Management of Benign Prostatic Hyperplasia in the United StatesJournal of Urology, 1995
- Adverse Effects of ??1-Adrenergic Blocking DrugsDrug Safety, 1994
- Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors.Circulation Research, 1983